Calamos Advisors
PBAXU

Calamos Advisors’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Calamos Advisors’s Portfolio PBAXU Stock Details PBAXU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,000
Closed -$252K – 1397
2022
Q2 		$252K Hold
25,000
– – ﹤0.01% 1105
2022
Q1 		$252K Hold
25,000
– – ﹤0.01% 1110
2021
Q4 		$252K Buy
+25,000
New +$253K ﹤0.01% 1078

Other funds holding PBAXU

SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Calamos Advisors's PBAXU Position: Q3 2022 in Review

Calamos Advisors sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q3 2022, closing a stake of 25,000 shares — an estimated $252K sold.

Calamos Advisors first reported a position in PBAXU in Q4 2021 and held it in 3 quarters. The position peaked at $252K in Q2 2022. 21 funds tracked by Wall St. Rank hold PBAXU as of Q3 2022.

  • Calamos Advisors reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q3 2022 after selling out during the quarter.
  • Calamos Advisors sold 25,000 Phoenix Biotech Acquisition Corp. Unit shares in Q3 2022, an estimated $252K.
  • Calamos Advisors first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 3 quarters.
  • Calamos Advisors's Phoenix Biotech Acquisition Corp. Unit position peaked at $252K in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q3 2022.

Based on Calamos Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.